Sustained pharmacological inhibition of δPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats

Xin Qi,¹ Koichi Inagaki,¹ Raymond A. Sobel,¹,² and Daria Mochly-Rosen¹

¹Department of Chemical and Systems Biology and ²Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.

Hypertensive encephalopathy is a potentially fatal condition associated with cerebral edema and the breakdown of the blood-brain barrier (BBB). The molecular pathways leading to this condition, however, are unknown. We determined the role of δPKC, which is thought to regulate microvascular permeability, in the development of hypertensive encephalopathy using δV1-1 — a selective peptide inhibitor of δPKC. As a model of hypertensive encephalopathy, Dahl salt-sensitive rats were fed an 8% high-salt diet from 6 weeks of age and then were infused s.c. with saline, control TAT peptide, or δV1-1 using osmotic minipumps. The mortality rate and the behavioral symptoms of hypertensive encephalopathy decreased significantly in the δV1-1–treated group, which suggests that δPKC may specifically act to dysregulate tight junction components. Together, these results suggest that δPKC plays a role in the development of hypertension-induced encephalopathy and may be a therapeutic target for the prevention of BBB disruption.

Introduction

Hypertensive encephalopathy is a complex condition that is characterized by a rapid onset of headache, nausea, impaired consciousness, and visual disturbances (1–3). Hypertensive encephalopathy in humans is associated with breakdown of the blood-brain barrier (BBB) to fluid, cells, and macromolecules, especially in the cerebral cortex and in the basal ganglia (1). The change in permeability mainly affects intracerebral arteries and leads to cerebral edema, which is invariably fatal in the absence of antihypertensive treatment (2). Although antihypertensive treatment reduces the structural changes in the cerebral vessels (4), the molecular basis for hypertensive encephalopathy is not well understood.

The BBB is an essential structure for maintaining CNS homeostasis. It consists of vascular endothelia surrounded by a layer of astrocytic foot processes and microglia (5–7). Tight junctions of the BBB restrict paracellular permeability (8–10). When the barrier integrity is disrupted, inflammatory cells and fluid penetrate the brain, which results in edema and cell death (5–7). Changes in BBB function are documented in several diseases, including stroke, muscular dystrophy, multiple sclerosis, Alzheimer disease, and septic encephalopathy (11–15). Consequently, protection of the BBB has become an important target for drug development.

Nonstandard abbreviations used: AQP4, aquaporine 4; BBB, blood-brain barrier; df, degrees of freedom; DS, Dahl salt-sensitive; ZO-1, zonula occludens 1.

Conflict of interest: Daria Mochly-Rosen is the founder of KAI Pharmaceuticals Inc., a company that plans to bring PKC regulators to the clinic. However, none of the work described here is in collaboration with or supported by the company. The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 118:173–182 (2008). doi:10.1172/JCI32636.

The PKC family of serine/threonine kinases consists of 10 different isoforms, which are further classified into 3 major categories: conventional PKCs (α, βI, βII, and γ), novel PKCs (δ, ε, η, and θ), and atypical PKCs (ζ, λ/ι, and μ). PKC α, βI, βII, γ, δ, and ε mRNA and proteins are present in the CNS, which indicates unique cellular and subcellular localizations (16). Direct activation of PKC by phorbol esters increases the flux of fluid and macromolecules through the microvascular wall (17). Inhibitors of PKC, such as H7, calphostin C, and chelerythrine, reduce the increased endothelial permeability that is induced by hydrogen peroxide, neutrophils, and platelet-activating factor (18–20). More importantly, PKC activation and subsequent vascular barrier dysfunction may be involved in the progress of circulatory disorders associated with atherosclerosis (21), ischemia/reperfusion injury (22), and diabetic retinopathy (23). Thus, PKC is considered to be a potential mediator of microvascular permeability under various stimulated conditions. However, specific PKC isoforms have distinct effects on the function and the integrity of epithelial cell and endothelial cell barriers in vitro and in vivo. Thus, direct targeting of specific PKC isoforms may help to identify which PKC isoform regulates microvascular permeability. Our previous report showed that δPKC plays a deleterious role in stroke and neuronal cell death and that inhibition of δPKC by single injection of the δPKC selective inhibitor δV1-1 (0.2 mg/kg) reduces cerebral damage following a middle cerebral artery occlusion stroke model by more than 70% (24). Furthermore, δPKC-null mice exhibit reduced infarction following middle cerebral artery occlusion (25). However, the role of δPKC in hypertension-induced encephalopathy and BBB disruption has not been determined.

A lethal form of hypertension has been shown to develop in Dahl salt-sensitive (DS) rats fed a high-salt diet from an early age (26).
Behavioral symptoms of encephalopathy and stroke, disruption of the BBB, and the occurrence of intracerebral hemorrhage in DS rats fed a high-salt diet were noted (27, 28). Using the DS rat model, we investigated the role of δPKC in hypertensive encephalopathy. We used various PKC-selective regulators (29) and found that the δPKC-specific peptide inhibitor δV1-1 reduced the incidence of hypertension-induced encephalopathy by protecting the integrity of the BBB. The molecular basis of these events was also studied.

Results δV1-1 decreases the mortality rate of hypertensive rats. Hypertensive DS rats develop symptoms of encephalopathy and stroke between 11 and 15 weeks of age while maintaining normal cardiac functions (30). During this period, about 60% of the animals die of encephalopathy. Around 16–17 weeks of age, the surviving rats (about 40% of the animals) begin to develop heart failure, and the animals die at about 21 weeks of age (30). Because we focused on encephalopathy, we only studied animals between the ages of 11 and 15 weeks. The animals were treated with various isozyme-selective PKC inhibitors using an osmotic pump to obtain sustained delivery. A great delay in mortality was observed only in the hypertensive rats that were treated with δV1-1, the δPKC-selective inhibitor (Figure 1A). Whereas rats in the vehicle-treated group died by 15 weeks, only 3 of 18 rats in the δV1-1–treated group died. Treatment with other PKC isozyme-specific regulating peptides, including the εPKC-selective inhibitor and the βIIIPKC-selective inhibitor, did not significantly affect survival of the hypertensive DS rats. Furthermore, rats treated with δV1-1 at the age of 15 weeks showed no improvement in cardiac function (as evaluated by fractional shortening) compared with rats treated with saline or TAT control peptide (Figure 1B). Therefore, it is unlikely that δV1-1 treatment improved survival by ameliorating cardiac dysfunction. Together, these data suggest that, of all the PKC isozymes, δPKC has a specific deleterious effect, i.e., it induces brain injury in hypertensive rats.

δV1-1 treatment reduces encephalopathy symptoms in hypertensive rats. We next identified the type and severity of the encephalopathy symptoms using a new group of animals. Because the assessment of symptoms is subjective, the observer was blinded to the treatments. Of the 24 saline-treated rats, 4 exhibited twitching, 3 displayed symptoms of fore- and hind-limb paralysis, and 12 exhibited severe lethargy (the most serious neurological deficit). The TAT-treated group exhibited neurological deficits similar to those of the saline-treated group. In contrast, of the 24 δV1-1–treated rats, 0 showed severe lethargy, 1 had a seizure, 2 exhibited twitching behaviors, and 3 had limb paralysis. Rats in the vehicle-treated group with symptoms of encephalopathy usually died within 3 days. However, in the δV1-1–treated group, disease was less severe; the 1 rat that had a seizure and the 2 rats that exhibited twitching behaviors did not die of hypertensive encephalopathy. These data suggest that δV1-1 may reverse neurological dysfunction. However, because treatment began before the onset of neurological dysfunction, the therapeutic effect of δV1-1 after the symptoms occurred could not be discerned. We are currently investigating the benefit of δPKC inhibition treatment on hypertensive encephalopathy once symptoms have manifested. This experiment will help determine whether δPKC inhibition will benefit patients with hypertension crisis and encephalopathy symptoms. Here we observed amelioration of the original neurological deficits in the group of rats administered δV1-1, which was not observed in the control-treated groups (Figure 1C).

δV1-1 has no effect on blood pressure. Because encephalopathy is induced by hypertension, we confirmed that none of the PKC regulators affected blood pressure. In rats, a systolic blood pressure of 150 mmHg is considered the threshold for hypertension (27). DS rats fed 8% NaCl for 5 weeks (from 6 to 11 weeks of age) showed severe hypertension (241 ± 37 mmHg). Sustained treatment with δV1-1 from 11 to 15 weeks (1.0 mg/kg/d) did not alter the elevated blood pressure as compared with the saline- or TAT-treated animals (Figure 1D).
Sustained delivery of δV1-1 peptide inhibits δPKC translocation. We next confirmed that δV1-1, the δPKC-selective inhibitor peptide, exerted its biological effect and selectively inhibited δPKC activity. Translocation of PKC from the soluble to the particulate fraction is a marker for PKC activation (31). We therefore assessed δPKC translocation in the hypertensive rat model and the effects of the treatments on the translocation. In 13-week-old rats, there was a 40% increase in δPKC translocation in the saline- and TAT-treated groups relative to the normotensive rats (Figure 2A), which indicated that δPKC is activated by hypertension. In rats treated with δV1-1, the increase in δPKC translocation was reduced by 70% to only about 15% above the basal value (Figure 2A). As expected, δV1-1 did not affect εPKC translocation, which indicated the selectivity of the inhibitor (Figure 2A). Furthermore, there were no changes in the total level of δPKC in any of the treatment groups (Figure 2B). In addition, hypertension-induced phosphorylation of δPKC (Ser643) was significantly inhibited by δV1-1 treatment, by 80%, compared with the saline-treated group (Figure 2C).

δV1-1 reduces BBB permeability. To determine the extent of BBB disruption caused by hypertension and the effects of δPKC inhibition, we evaluated the extravasation of Evans blue dye into the brain parenchyma, a sign of BBB permeability (32). In the TAT-treated group, 5 of 6 rats showed Evans blue extravasation into brain parenchyma. In contrast, only 2 of 6 rats treated with δV1-1 showed some increase in BBB permeability (Figure 3A). The amount of Evans blue dye in the brain parenchyma was greater in the TAT-treated group (3.6 ± 0.7 mg/brain) than in the δV1-1-treated group (1.6 ± 0.3 μg/brain) (Figure 3B; P < 0.01). As expected, no Evans blue extravasation was observed in control normotensive rats fed a low-salt diet (0.3% NaCl).

Immunoreactivity of δPKC in brain microvessels in DS rats. Endothelial cell and astrocyte endfoot surrounding the brain capillaries form the BBB to limit transcellular flux across the vasculature (33). We
therefore assessed δPKC localization in these structures using immunogold electron microscopy. In contrast with normotensive DS rats fed a low-salt diet, the TAT-treated hypertensive rats had a discontinuous basal lamina and much thicker capillary endothelial layer in the microvessels and more immunolabeling of δPKC in the endothelial cells forming the border of the capillary (Figure 4A). In contrast, relative to the TAT-treated hypertensive rats, the δV1-1–treated rats showed a clear basal lamina layer, thin endothelial cell layer, and less δPKC labeling in the endothelial cells (Figure 4A, right vs. middle).

Astrocyte swelling indicates BBB damage. In the hypertensive rats treated with TAT, we found a large number of gold particle (δPKC immunoreactivity) label that was localized in the swollen astrocyte endfeet covering the vessel wall, whereas no gold particles were observed in the normotensive rats (Figure 4B, middle vs. left). Treatment with δV1-1 reduced δPKC labeling, and the shape of astrocyte endfeet appeared normal (Figure 4B, right). The levels of aquaporin 4 (AQP4; a marker of astrocyte endfoot processes) appear reduced when the BBB is disrupted (34, 35). Immunohistochemistry assessment showed that the perivascular astrocyte processes enveloping the control vessel walls had a strong AQP4 immunoreactivity in normotensive rats. In the TAT-treated hypertensive rats, the vessels had a more discontinuous and faint staining of AQP4 at their abluminal side, and this abnormal staining was corrected in the δV1-1–treated group (Figure 4C). In addition, long-term treatment with δV1-1 may alter the density of specific cells, such as cerebral endothelial cells, astrocytes, and pericytes, as a means to improve BBB function. Future studies will address this possibility. Collectively, these data suggest that δPKC activation mediates, at least in part, the disruption of brain microvasculature in hypertensive rats.

Figure 4
Sustained δV1-1 treatment preserves the integrity of the cerebral capillaries of hypertensive rats. Brain cortex samples were collected from 13-week-old DS rats treated with either TAT or δV1-1 and stained with δPKC using the immunogold labeling method. (A) Middle: δPKC immunogold labeling in endothelial cells and improved morphology of basal lamina (BL) after δV1-1 treatment were noted. L, vessel lumen. A scheme of the area studied is shown at left; a histogram depicting quantitative data of gold particles in endothelial cells is shown at right. Data are mean ± SEM (n = 3 animals per group). F = 16.75, df = 2. *P < 0.05 versus TAT treatment; #P < 0.05 versus normotensive rats. (B) Increased δPKC levels in the endfeet of astrocytes (AS) that envelop vessel walls were seen in rat brains from hypertensive rats, which were blocked by δV1-1 treatment. (C) Immunohistochemical analysis of astrocytes surrounding cerebral vessels. Frozen sections of rats treated with TAT or δV1-1 were stained with AQP4, a marker of astrocyte endfoot process. Immunostaining of AQP4 around the cerebral vessel wall was observed. n = 3 rats per group.
δV1-1 blocks disorganization of tight junction in hypertensive DS rats. The tight junction is an essential component of the BBB. A large number of studies showed that altered BBB permeability is associated with disruption of tight junction components (8–10, 13). At the molecular level, the tight junction proteins, including claudins, occludin (a transmembrane protein), and ZO-1, ZO-2, and ZO-3 (members of the membrane-associated guanylate kinase homolog family), interact with each other and with the actin cytoskeleton to form tight junction complexes (8, 9). Alteration in occludin and ZO-1 subcellular distribution has been used as a marker for disrupted tight junction and epithelial barrier (13, 35, 36). We therefore determined the subcellular distribution of ZO-1 and occludin using Western blot analysis of detergent-soluble (membrane and cytosolic fractions) and detergent-insoluble fractions (cytoskeleton-enriched fraction). We found less of the tight junction proteins (ZO-1 and occludin) in the detergent-insoluble fraction and more in the detergent-soluble fraction (Figure 5A). As compared with normotensive rats, there was a 40% ± 2% decrease in the level of cytoskeleton-element associated ZO-1 and a corresponding increase in soluble ZO-1 in 13-week-old hypertensive rats treated with TAT. Treatment with δV1-1 significantly blocked this translocation of ZO-1 from the cytoskeleton to the detergent-soluble fraction (Figure 5). We also found that the translocation of occludin from the cytoskeleton-element–associated fraction to the soluble fraction was similar to that of ZO-1 and that δV1-1 treatment blocked this translocation compared with that in the TAT-treated group (Figure 5). No significant changes in the total protein levels of ZO-1 and occludin were observed in either treatment group (Figure 5C). These data strongly indicate that δV1-1 treatment blocks the disruption of the structure of tight junctions caused by hypertension in the DS rat model.

Next, using immunofluorescence we examined the cellular distribution of these 2 tight junction proteins in the hypertensive DS rat brains treated with TAT or δV1-1. In the normotensive rats, ZO-1 and occludin colocalized with CD31 (an endothelial cell marker) and exhibited discrete dots or line-like staining. However, the staining pattern was altered in hypertensive rat brains treated with TAT; the staining of both tight junction proteins was diffuse and appeared aggregated. This extensive disorganization of ZO-1 and occludin in TAT-treated rats was reversed in the hypertensive rats treated with δV1-1 (Figure 6, A and B). Thus, the changes in the cellular distribution of the tight junction proteins ZO-1 and occludin in the hypertensive rats were associated with δPKC activation, which suggests that δPKC mediates disruption of the organization of tight junction proteins and the consequent increased vascular permeability and results in BBB breakdown.

δPKC phosphorylates ZO-1 in hypertensive rats. ZO-1 is a phosphorylated protein and contains 34 repeats of a PKC phosphorylation consensus motif, which suggests that ZO-1 is a substrate of PKC signaling (37). Furthermore, ZO-1 phosphorylation correlates with tight junction disruption (38–40). To begin elucidating how δPKC disrupts
tight junctions, we determined the changes in phosphorylation of ZO-1 in the hypertensive DS rat model. In hypertensive DS rats, membrane-associated ZO-1 was phosphorylated twice as much as in the normotensive rats (Figure 7). Importantly, δV1-1 treatment completely blocked this rise in ZO-1 phosphorylation (Figure 7). The data suggest that δPKC phosphorylates ZO-1 directly or increases its phosphorylation indirectly and consequently leads to disruption in ZO-1 function and an increase in BBB permeability.

Discussion
In the present study, we demonstrated for the first time to our knowledge that sustained inhibition of δPKC, using a δPKC-
selective inhibitor peptide, significantly reduced the incidence and symptoms of hypertensive encephalopathy in a hypertensive DS rat model. We also found that neuroprotection by the δPKC inhibitor was associated with the prevention of BBB breakdown, although blood pressure remained high.

In DS rats fed a high-salt diet, BBB permeability develops before the appearance of symptoms of brain damage (27, 28). We found that δV1-1 decreased BBB permeability by about 60% as measured by Evans blue extravasation. Moreover, inhibition of δPKC in endothelial cells and capillary barrier–associated astrocyte endfeet in the DS rat brain was linked to ameliorating morphological dysfunction in the brain microvasculature. Thus, prevention of BBB permeability via treatment with δV1-1 might have been responsible for the amelioration of neurological deficits and the subsequent increase in survival in the absence of an effect on blood pressure. Thus, the mechanism is distinct from that of kallikrein, a protein implicated in the pathogenesis of hypertension and renal diseases, which was shown to decrease the mortality rate from stroke in the DS rat model by reducing hypertension (41).

In normal control animals, δPKC inhibition (or activation) exerts no effect, including no effect on heart rate and blood pressure (data not shown). Moreover, δV1-1 has been given to patients with acute myocardial infarction with no adverse effects (42). Under ischemia/reperfusion conditions, the benefits of δPKC inhibition are numerous — it reduces apoptosis (43), necrosis (29, Figure 7

Sustained treatment with δV1-1 inhibits the serine/threonine phosphorylation of ZO-1 in hypertensive rat brain. Brain tissues were fractionated, and samples from the Triton-soluble membranal fraction were immunoprecipitated with anti–ZO-1 antibody. Top: typical examples of 6 independent experiments. Bottom: quantification of ZO-1 phosphorylation. Data are mean ± SEM (n = 6 rats per group). F = 6.58, df = 2. *P < 0.05 versus TAT treatment; †P < 0.05 versus rats fed a low-salt diet. In the absence of ZO-1 antibodies in the immunoprecipitation, no ZO-1 was detected by Western blot analysis (not shown).

Figure 8

Scheme depicting a possible mechanism of δPKC-mediated tight junction dysfunction, increased BBB permeability leading to hypertensive encephalopathy, and potential sites of action of the δPKC inhibitor δV1-1. Left: scheme of a cerebral microvessel. Middle: enlargement of the area indicated in the red box at left. Right: scheme of a similar area in a hypertensive animal. Hypertension causes swelling of endothelia and endfeet of astrocytes surrounding the small vessels of brain and increases immunoreactivity of δPKC (right versus middle). Serine and threonine phosphorylation of ZO-1 by δPKC activation leads to the disruption of ZO-1 in the microvasculature and reduces its level in the tight junction (TJ). Consequently, BBB permeability increased. δPKC accumulation in endfeet is likely to lead to increased phosphorylation, but the substrates have not yet been identified. Inhibition of δPKC by δV1-1 inhibits ZO-1 phosphorylation, which, in turn, reduces changes in TJ morphology of the microvasculature and increases BBB impermeability.

Figure 8
44), and infarct size in the heart (29) and the brain (24). δPKC inhibition also inhibits pyruvate dehydrogenase kinase activity and thus accelerates ATP regeneration (45). Furthermore, we previously showed that the protective effects of acute treatment with δV1-1 in a transient cerebral ischemia model were mediated, at least in part, by the inhibition of apoptosis (24). We also found that the increased blood flow induced by δV1-1 treatment in the ischemic model may play a role in neuroprotection (46). However, the mechanisms underlying hypertension-induced cerebral damage in DS rats are not identical to those of the transient cerebral ischemia model, and δV1-1 may exert beneficial effects in DS rats via a different mechanism, the nature of which remains to be fully elucidated.

A number of studies have shown that activation of PKC regulates increased vascular permeability in many cell culture models. However, conflicting data on the critical role of PKC in this process have been described. Hypoxia and posthypoxic reoxygenation-induced increases in BBB paracellular permeability activate several PKC isozymes in rat brain microvessel endothelial cells (47). Overexpression of βIPKC in human dermal microvascular endothelial cell augments phorbol ester–stimulated increases in albumin permeability (48), whereas overexpression of a dominant negative δPKC in these cells interferes with the bromostatin–mediated decrease in transepithelial electrical resistance—a marker of barrier function (49). Furthermore, overexpression of δPKC decreases transepithelial electrical resistance in LLC-PK1 cells, which are derived from pig kidney cortex (50). Oxidants induce loss of intestinal epithelial barrier integrity through the activation of δPKC (51), and δPKC is required for PMA- and 1,2-diacylglycerol–induced hyperpermeability in pulmonary microvascular endothelial cells (52). Thus, whereas these cell culture studies have shown the potential role of α, βI, and δPKC in barrier permeability, there is still some uncertainty about the specific roles of the isozymes. Our study is the first to our knowledge to provide direct evidence of BBB disruption caused by δPKC activation in an in vivo animal model. Although βIPKC is activated in the DS rat model (30), it is unlikely to be critical in this function because the βIPKC inhibitor did not affect the incidence of encephalopathy (data not shown).

We also elucidated a potential molecular basis for the δPKC neuron-protective effect as depicted schematically in Figure 8. Inhibition of δPKC in endothelial cells and capillary barrier–associated astrocyte endfeet in DS rat brain decreased endothelial and astrocyte swelling and BBB breakdown (Figure 8). Treatment with δV1-1 significantly blocked the change in subcellular location of ZO-1 and occludin at the tight junction, which suggests that the modification of tight junction proteins by δPKC is responsible for the increase in BBB permeability caused by hypertension (Figure 8). Furthermore, we found that ZO-1 was phosphorylated at serine and threonine residues and that δV1-1 treatment inhibited the phosphorylation of ZO-1. Indeed, serine/threonine phosphorylation changes are known to regulate the function of both existing and assembling tight junction proteins (53), and increased serine and threonine phosphorylation of ZO-1 enhances BBB permeability (36, 40, 54). Because a lack of ZO-1 prevents the targeting of occludin to the junctional contacts, changes in ZO-1 localization at the tight junction are coupled to alterations in the recruitment of other tight junction proteins at endothelial membranes and consequently lead to an increase in vascular permeability (8, 10). Thus, ZO-1 may serve as a direct target for δPKC in hypertensive encephalopathy or may be a substrate of a downstream kinase of δPKC.

Alterations in the BBB and tight junctions correlate with reduced AQP immunoreactivity in perivascular glial endfeet (34, 35). This finding supports our data, which indicate that swollen and/or degenerated glial endfeet with a reduction in AQP4 content is relevant to alterations in tight junction proteins. AQP4 can be phosphorylated by PKC in vitro (54), and activation of PKC by phorbol 12,13-dibutyrate decreases AQP4 levels in astrocytes via phosphorylation at Ser180 (55). In the present study, we found that hypertension induced a significant increase in δPKC levels and a decrease in AQP4 in the surrounding vessel wall. Furthermore, both δPKC and AQP4 were normalized by treatment with the δPKC inhibitor δV1-1. It is possible that activation of δPKC in astrocytes induced by hypertension decreases AQP4 levels via phosphorylation, which, in turn, leads to astrocyte swelling and a subsequent increase in BBB permeability. Activated astrocytes can release inflammatory mediators such as tumor necrosis factor and interleukin-1, which can also increase the permeability of the BBB (56, 57). Moreover, it was shown in δPKC-null mice that neutrophil infiltration into the brain is reduced and proinflammatory cytokines and chemokines are inhibited following stroke (25). Thus, it is possible that increased δPKC in astrocytes following hypertension may, in part, be due to astrocyte-derived inflammatory factors. However, this remains to be determined.

In the present study, we also examined the immunoreactivity of δPKC in postmortem samples of human brain to determine whether the same alteration of δPKC activation in the microvasculature occurs in humans suffering from hypertension (see Supplemental Methods; supplemental material available online with this article; doi:10.1172/JCI32636DS1). Data for 3 male patients are provided in Supplemental Figure 1. Patients 07A22 and 07A29 both had a history of hypertension, whereas the third patient (07A31) had no history of hypertension and died of amyotrophic lateral sclerosis (normal basal ganglia and cortex were observed). All the samples show staining of the vessel wall smooth muscle. However, it appears that the 2 patients with a history of hypertension have more δPKC staining in the arteriolar endothelial cells and astrocytes than does the nonhypertensive patient (Supplemental Figure 1).

Obviously, the number of samples in this study was too small to be conclusive, but these data are consistent with our animal data and suggest that hypertension-induced pathology in human brains may be associated with δPKC activation in the cerebral microvasculature. A larger study with many more samples, including age- and sex-matched patients with similar comorbidity factors, such as diabetes, obesity, and smoking habits, is required to make a definitive conclusion.

In conclusion, our findings suggest that δPKC activation is a key signaling event that dysregulates the structural and functional integrity of tight junctions and BBB, which leads to brain damage and hypertension-induced encephalopathy. Our data suggest that δV1-1 has therapeutic potential for the prevention or reduction of cerebrovascular injury in hypertension-induced encephalopathy in rats. If a similar mechanism occurs in humans, a δPKC inhibitor may be useful for patients at risk of hypertension-induced encephalopathy and stroke, common causes of morbidity and mortality, especially among people of African and Asian descent.

Methods
Protease and phosphatase inhibitor cocktails, trichloroacetic acid, paraformaldehyde, and Evans blue dye were purchased from Sigma-
Alldrich. Antibodies against βPKC were purchased from Santa Cruz Biotechnology Inc., antibodies against ZO-1 and occludin were purchased from Zymed Biotechnology, and GAPDH antibody, clone 6C5, was purchased from Advanced Immunochemical. Antibodies for the anti-serine 643 phosphorylation of βPKC and anti-serine and threonine phosphorylation were from Cell Signaling Technology. Anti-mouse IgG and anti-rabbit IgG, peroxidase-linked species-specific antibodies, were purchased from Amersham Biosciences. Anti-CD31 and anti-AQP4 were from Chemicon.

The βPKC-specific antagonist peptide BV-1-1 (βPKC inhibitor, amino acids 8–17 [SFSYELGSL]) was synthesized by American Peptides and conjugated to TAT-carrier peptide (amino acids 47–57) via a cysteine-cysteine S-S bond at their N termini, as previously described (29).

**Animals and treatments.** Male DS rats, aged 4–5 weeks, were obtained from Harlan. The rats were fed a high-salt diet containing 8% NaCl from the age of 6 weeks and were maintained to 15 weeks of age. From the age of 11 weeks, the rats were subcutaneously infused with 0.9% saline, control carrier TAT, or the age of 11 weeks, the rats were subcutaneously infused with 0.9% saline, control carrier TAT, or the age of 11 weeks, the rats were subcutaneously infused with 0.9% saline, control carrier TAT, or the age of 11 weeks, the rats were subcutaneously infused with 0.9%

The systolic blood pressure was measured biweekly with a tail-pulse pick-up method with a Statham pressure transducer as recorded on a PowerLab voltmeter. Results are presented as milligrams of Evans blue by comparing the concentration in the supernatant was measured at 610 nm with a spectrophotometer. Measurement of BBB permeability. Rats were deeply anesthetized with isoflurane (3%), and Evans blue dye (30 mg/ml in 0.9% saline) was injected (30 mg dye/kg) into the femoral vein. After 30 minutes, the rats were removed. Fractional shortening was measured by transthoracic echocardiography (Vivid 7; GE). The animals were euthanized at the end of 15 weeks. The animals were coded so that the observer was blinded to the treatment.

**Tissue preparation.** The animals were deeply anesthetized with isoflurane (3%) and transcardially perfused with PBS. The brains of some animals were removed immediately and quickly frozen in liquid nitrogen. Some animals were transcardially perfusion-fixed with 4% paraformaldehyde fixative and further postfixed in paraformaldehyde for 1 h. The brains were then cryoprotected by immersion in a 30% sucrose solution for 24 h at 4°C and then frozen rapidly in Tissue-Tek (Fisher Biotechnology) for immunostaining. All samples were stored at –80°C.

**Measurement of BBB permeability.** Rats were deeply anesthetized with isoflurane (3%), and Evans blue dye (30 mg/ml in 0.9% saline) was injected (30 mg dye/kg) into the femoral vein. After 30 minutes, the rats were perfused with 200 ml of PBS by transcardiac infusion, and the brains were removed. After the cerebellum and brainstem were removed, the cerebral hemispheres were homogenized in 2 ml of 0.1 M PBS. After centrifugation for 30 min at 4°C, the Triton-soluble particulate fraction was isolated, and the Triton-insoluble fraction pellets were dissolved in SDS sample buffer. The samples were analyzed by Western blot. The Triton-soluble particulate fraction was isolated, and the Triton-insoluble fraction pellets were dissolved in SDS sample buffer. The samples were analyzed by Western blot.

**Western blot.** Protein concentrations were determined by Bradford assay. Proteins from each fraction were resuspended in Laemmli buffer, loaded on 10% SDS-PAGE gels, and transferred onto nitrocellulose membranes. Membranes were probed with the indicated antibody followed by visualization by ECL and quantitated using NIH ImageJ software.

**Immunohistochemistry.** The indirect streptavidin-biotin-peroxidase method was used, and sections were treated with 0.3 % H₂O₂ for 5 minutes at room temperature. Sections were incubated in primary anti-rabbit AQP4 (1:200) antibodies (1:1,000 dilution).

**Statistics.** All data are expressed as the mean ± SEM. One-way ANOVA with a post-hoc Tukey’s honestly significant difference test was used to determine difference between the groups. The F value with degrees of freedom (df) was provided. Survival was analyzed by conducting a standard Kaplan-Meier analysis with a log-rank test. The significance of changes in neurological symptoms was analyzed with a Fisher’s exact test. A P value less than 0.05 was considered significant.

**Acknowledgments**

This work was supported by NIH NS grant 044350 to Daria Mochly-Rosen.

Received for publication May 9, 2007, and accepted in revised form October 24, 2007.

**Address correspondence to:** Daria Mochly-Rosen, Department of Chemical and Systems Biology, Stanford University School of Medicine, CCSR, Room 3145A, 269 Campus Drive, Stanford, California 94305, USA. Phone: (650) 725-7720; Fax: (650) 723-4686; E-mail: mochly@stanford.edu.

Koichi Inagaki’s present address is: Otsu Red-Cross Hospital, Shiga, Japan.

**Research article**

Shiga, Japan.


